Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson’s disease

Fig. 1

The expression of NLRP3 protein exhibited the most changes in the midbrain, the liver, and the BMDM of MPTP-induced mice. a The expression of NLRP1 and NLRP3 was not only higher in the midbrain of the acute MPTP model mice, but also in the MPTP/p model mice. b The analysis of NLRP1, NLRP2, NLRP3, NLRC4, and AIM2 expression in the midbrain of the acute MPTP model mice (left), as well as the analysis in the MPTP/p model mice (right). c The expressions of NLRP2, NLRP3, and NLRC4 were higher in the liver of the acute MPTP model mice. The expressions of NLRP2 and NLRP3 were higher compared to the saline group in the liver of MPTP/p model mice. d The analysis of NLRP1, NLRP2, NLRP3, NLRC4, and AIM2 expression in the liver of the acute MPTP model mice (left), as well as the analysis in the MPTP/p model mice (right). e The expression of NLRP2 and NLRP3 was not only higher in the BMDM of the acute MPTP model mice, but also in the MPTP/p model mice. f The analysis of NLRP1, NLRP2, NLRP3, NLRC4, and AIM2 expression in the BMDM of the acute MPTP model mice (left), as well as the analysis in the MPTP/p model mice (right) (n = 4 animals per condition). Samples were collected after 7 days of last MPTP injection. Data is presented as mean ± SEM, Student’s T test, **p < 0.01, *** p < 0.001 versus the corresponding saline group

Back to article page